{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:05:20Z","timestamp":1770465920964,"version":"3.49.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of this study is to investigate the effects of sarilumab on unacceptable pain [UP; visual analogue scale (VAS) &amp;gt;40\u2009mm] and inflammation in patients with moderately-to-severely active rheumatoid arthritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this post hoc analysis of the KAKEHASI study, 243 patients received methotrexate with sarilumab 150 or 200\u2009mg or placebo every other week, over 52\u2009weeks. The proportion of patients with UP and correlations of changes in pain VAS from baseline with uncontrolled inflammation (C-reactive protein \u22651\u2009mg\/dl) and disease activity indices were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Almost 80% of patients (192\/243) had UP at baseline, including \u223c60% of patients with uncontrolled inflammation. Among patients receiving sarilumab, inflammation decreased rapidly, with 90% of patients achieving controlled inflammation by Week 2, while 63.1% continued to have UP. The proportion of patients with UP further decreased by Week 16 (28.5%, sarilumab vs. 64.0%, placebo). By Week 52, only \u223c10% of patients had UP. Changes in pain VAS correlated with most disease activity indices and patient-reported outcomes. However, marked correlations between changes in pain VAS and C-reactive protein were observed only at Week 16.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Sarilumab treatment reduced UP and inflammation in Japanese patients with rheumatoid arthritis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/road073","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:03:12Z","timestamp":1692720192000},"page":"670-677","source":"Crossref","is-referenced-by-count":5,"title":["Effect of\u00a0sarilumab on\u00a0unacceptable pain and\u00a0inflammation control in\u00a0Japanese patients with moderately-to-severely active rheumatoid arthritis: <i>Post hoc<\/i> analysis of\u00a0a Phase III study (KAKEHASI)"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Specialty Care Medical, Sanofi K.K. , Tokyo, Japan"},{"name":"Medical Affairs, Asahi-Kasei Pharma Corporation, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"van Hoogstraten","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi , Bridgewater, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kato","sequence":"additional","affiliation":[{"name":"Medical Affairs, Asahi-Kasei Pharma Corporation , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"2024082813134547900_R1","doi-asserted-by":"crossref","DOI":"10.1186\/s41232-020-00133-8","article-title":"Rheumatoid arthritis","volume":"40","author":"Tanaka","year":"2020","journal-title":"Inflamm Regen"},{"key":"2024082813134547900_R2","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2076328","article-title":"Pain mechanism in\u00a0rheumatoid arthritis: from cytokines to central sensitization","volume":"2020","author":"Cao","year":"2020","journal-title":"Mediators Inflamm"},{"key":"2024082813134547900_R3","doi-asserted-by":"crossref","DOI":"10.1186\/ar2684","article-title":"Enhanced reactivity to pain in\u00a0patients with rheumatoid arthritis","volume":"11","author":"Edwards","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2024082813134547900_R4","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-019-0100-9","article-title":"Disease activity flares and\u00a0pain flares in\u00a0an early rheumatoid arthritis inception cohort; characteristics, antecedents and\u00a0sequelae","volume":"3","author":"McWilliams","year":"2019","journal-title":"BMC Rheumatol"},{"key":"2024082813134547900_R5","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/acr.21747","article-title":"Minimum clinically important improvement and\u00a0patient acceptable symptom state in\u00a0pain and\u00a0function in\u00a0rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and\u00a0hip and\u00a0knee osteoarthritis: results from a prospective multinational study","volume":"64","author":"Tubach","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024082813134547900_R6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/03009742.2020.1729404","article-title":"Unacceptable pain in\u00a0the BARFOT inception cohort of\u00a0patients with rheumatoid arthritis: a long-term study","volume":"49","author":"Svensson","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2024082813134547900_R7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/rheumatology\/keac659","article-title":"Disproportionate articular pain is a frequent phenomenon in\u00a0rheumatoid arthritis and\u00a0responds well to treatment with sarilumab","volume":"62","author":"Choy","year":"2023","journal-title":"Rheumatology"},{"key":"2024082813134547900_R8","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-016-0581-0","article-title":"Non-inflammatory causes of\u00a0pain in\u00a0patients with rheumatoid arthritis","volume":"18","author":"Boyden","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"2024082813134547900_R9","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2042-4","article-title":"Association between pain phenotype and\u00a0disease activity in\u00a0rheumatoid arthritis patients: a non-interventional, longitudinal cohort study","volume":"21","author":"Ten Klooster","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024082813134547900_R10","first-page":"94","article-title":"Pain mechanisms in\u00a0rheumatoid arthritis","volume":"35","author":"McWilliams","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2024082813134547900_R11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40744-019-00168-5","article-title":"Patient perceptions of\u00a0unmet medical need in\u00a0rheumatoid arthritis: a cross-sectional survey in\u00a0the USA","volume":"6","author":"Radawski","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2024082813134547900_R12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000887","article-title":"Long-term safety and\u00a0efficacy of\u00a0sarilumab plus methotrexate on disease activity, physical function and\u00a0radiographic progression: 5 years of\u00a0sarilumab plus methotrexate treatment","volume":"5","author":"Genovese","year":"2019","journal-title":"RMD Open"},{"key":"2024082813134547900_R13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40265-018-0929-z","article-title":"Sarilumab: A review in\u00a0moderate to severe rheumatoid arthritis","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"2024082813134547900_R14","article-title":"Kevzara (Sarilumab) Prescribing Information","author":"U.S. Food and Drug Administration"},{"key":"2024082813134547900_R15","article-title":"Summary of\u00a0Product Characteristics","author":"European Medicines Agency"},{"key":"2024082813134547900_R16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and\u00a0safety of\u00a0sarilumab monotherapy versus adalimumab monotherapy for\u00a0the treatment of\u00a0patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024082813134547900_R17","article-title":"Impact of\u00a0sarilumab on\u00a0unacceptable pain and\u00a0inflammation control in\u00a0moderately-to-severely active rheumatoid arthritis (RA) patients in\u00a03 phase 3 studies","volume":"21","author":"Bykerk","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024082813134547900_R18","article-title":"Sarilumab plus methotrexate in\u00a0patients with active rheumatoid arthritis and\u00a0inadequate response to methotrexate: results of\u00a0a randomized, placebo-controlled phase III trial in\u00a0Japan","volume":"21","author":"Tanaka","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024082813134547900_R19","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"Kasper","year":"2015","edition":"19th"},{"key":"2024082813134547900_R20","article-title":"Disease Activity and\u00a0Functional Status Assessments","author":"American College of Rheumatology"},{"key":"2024082813134547900_R21","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/aje\/153.12.1183","article-title":"Distribution of\u00a0serum C-reactive protein and\u00a0its association with atherosclerotic risk factors in\u00a0a Japanese population: Jichi Medical School Cohort Study","volume":"153","author":"Yamada","year":"2001","journal-title":"Am J Epidemiol"},{"key":"2024082813134547900_R22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/07853899709007474","article-title":"Pro- and\u00a0anti-inflammatory cytokines in\u00a0rheumatoid arthritis","volume":"29","author":"Isomaki","year":"1997","journal-title":"Ann Med"},{"key":"2024082813134547900_R23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/kep458","article-title":"Fibromyalgic rheumatoid arthritis and\u00a0disease assessment","volume":"49","author":"Pollard","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2024082813134547900_R24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OARRR.S291388","article-title":"Pain: a review of\u00a0interleukin-6 and\u00a0its roles in\u00a0the pain of\u00a0rheumatoid arthritis","volume":"13","author":"Sebba","year":"2021","journal-title":"Open Access Rheumatol"},{"key":"2024082813134547900_R25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1253\/circj.69.339","article-title":"Reference value for\u00a0C-reactive protein and\u00a0its distribution pattern in\u00a0Thai adults","volume":"69","author":"Charuruks","year":"2005","journal-title":"Circ J"},{"key":"2024082813134547900_R26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104402","article-title":"IL-6 involvement in\u00a0pain, fatigue and\u00a0mood disorders in\u00a0rheumatoid arthritis and\u00a0the effects of\u00a0IL-6 inhibitor sarilumab","volume":"149","author":"Atzeni","year":"2019","journal-title":"Pharmacol Res"},{"key":"2024082813134547900_R27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","article-title":"Interleukin-6 as a key player in\u00a0systemic inflammation and\u00a0joint destruction","volume":"8","author":"Fonseca","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2024082813134547900_R28","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-019-0356-0","article-title":"Response to IL-6 trans- and\u00a0IL-6 classic signalling is determined by the ratio of\u00a0the IL-6 receptor alpha to gp130 expression: fusing experimental insights and\u00a0dynamic modelling","volume":"17","author":"Reeh","year":"2019","journal-title":"Cell Commun Signal"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road073\/51218690\/road073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/4\/670\/58941475\/road073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/4\/670\/58941475\/road073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T14:40:49Z","timestamp":1724856049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/4\/670\/7247519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,17]]},"published-print":{"date-parts":[[2024,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road073","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2023,8,17]]}}}